Managers

SQZ Biotechnologies attracts $72 mln Series C

Massachusetts-based SQZ Biotechnologies, a cell therapy company, has raised $72 million in Series C financing. The investors included Everblue, Illumina Ventures, Invus, Orient Life, Viva Ventures Biotech Group, Bridger Healthcare Partners, Global Health Science Fund, GV, JDRF T1D Fund, NanoDimension and Polaris.

Ambys Medicines fetches $60 mln Series A

Redwood City, California-based Ambys Medicines, a developer of new medicines patients suffering from chronic liver diseases, has launched with $60 million in Series A financing. The investors were Third Rock Ventures and Takeda.

Hinge Health picks up $26 mln Series B

Hinge Health has secured $26 million in Series B funding, according to a post by CEO and co-founder Daniel Perez. Insight Venture Partners led the round with participation from Atomico. San Francisco-based Hinge Health is a provider of digital care for chronic musculoskeletal conditions.

Frazier hires EIR and senior associate

Frazier Healthcare Partners has named Dr. Tracy Saxton as an entrepreneur-in-residence and Vanessa Bhark as a senior associate. Saxton is the founder and CEO of Aucupo Biosciences while Bhark previously worked in corporate development at Gilead Sciences.

Therachon takes in $60 mln

Basel, Switzerland-based Therachon, a biotechnology company focused on rare diseases, has closed $60 million in financing. Novo Holdings led the round with participation from Cowen Healthcare Investments, Pfizer Ventures, Tekla Capital Management LLC, Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative.

Investor group commits $30 mln to merged OvaScience and Millendo

An investor syndicate that includes New Enterprise Associates, Frazier Healthcare Partners, Roche Venture Fund, Innobio managed by Bpifrance, Osage University Partners, Altitude Life Science Ventures, Adams Street Partners, and Longwood Fund has committed to invest $30 million in the newly merged OvaScienceSM and Millendo Therapeutics. OvaScience is a developer of treatments for women and couples struggling with infertility while Millendo Therapeutics Inc is a clinical-stage biopharmaceutical company focused on treating orphan endocrine diseases. The newly combined company is expected to operate under the name Millendo Therapeutics and trade on the NASDAQ under the ticker symbol "MLND."

Modulus Discovery snags $7.2 mln Series A

Tokyo-based Modulus Discovery Inc, an early-stage drug discovery company, has secured about $7.2 million in Series A funding. Fast Track Initiative Inc led the round with participation from PeptiDream Inc and DBJ Capital Co. Ltd, the venture capital subsidiary of Development Bank of Japan.

Akili Interactive nabs $13 mln

Boston and San Francisco Bay Area-based Akili Interactive, a prescription digital medicine company, has secured $13 million in funding. The investors included CLSA, Omidyar Technology Ventures, Digital Garage Group and Fearless Ventures.

SHS Fund V giving digital health a financial shot in the arm

July's Top 10: Capital continues to concentrate into mega venture deals